Trial record 16 of 1299 for:    Multiple Sclerosis

Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2006 by Sheba Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00230204
First received: September 29, 2005
Last updated: February 15, 2006
Last verified: January 2006
  Purpose

The purpose of this investigation is to assess the prevalence of infectious disease seropositivity (toxoplasmosis, rubella, cytomegalovirus [CMV]), herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2), syphilis, Epstein-Barr virus and H. pylori in a group of patients presenting with specific autoimmune diseases (rheumatoid arthritis [RA], undifferentiated connective tissue disorder [UCTD], Sjogren, antiphospholipid syndrome - APS, vasculitides, systemic lupus erythematosus [SLE], polymyositis, Hashimoto, multiple sclerosis, primary biliary cirrhosis [PBC], etc.), using the BioPlex 2200 and complementary EIA kits as compared to matched controls (by age, sex and ethnicity).


Condition Intervention Phase
Multiple Sclerosis
Procedure: Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Antibodies Screening in Multiple Sclerosis as a Part of an International Survey in Autoimmune Diseases.

Resource links provided by NLM:


Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • Determine antibodies to infectious agents immunoglobulin G (IgG), IgM in patients with multiple sclerosis

Secondary Outcome Measures:
  • Assess correlation between antibody levels to various infectious agents with clinical disease variables

Estimated Enrollment: 100
Study Start Date: September 2005
Estimated Study Completion Date: April 2006
Detailed Description:

The purpose of this investigation is to assess the prevalence of infectious disease seropositivity (toxoplasmosis, rubella, cytomegalovirus [CMV]), herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2), syphilis, Epstein-Barr virus and H. pylori in a group of patients presenting with specific autoimmune diseases (RA, UCTD, Sjogren, antiphospholipid syndrome - APS, vasculitides, SLE, polymyositis, Hashimoto, multiple sclerosis, PBC, etc.), using the BioPlex 2200 and complementary EIA kits as compared to matched controls (by age, sex and ethnicity).

We will assess in our Center 100 patients with multiple sclerosis for the antibody profile of different infectious agents. Comparative assessments will be performed with normal matched subjects.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Definite multiple sclerosis

Exclusion Criteria:

  • Intravenous immune globulin (IVIg) treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230204

Contacts
Contact: Anat Achiron, MD, PhD 972-3-5303811 achiron@post.tau.ac.il
Contact: Yehuda Shoenfeld, MD 972-3-5302652 shoenfel@post.tau.ac.il

Locations
Israel
Multiple Sclerosis Center, Sheba Medical Center Recruiting
Ramat-gan, Israel, 52621
Contact: Anne Levy    972-3-5303932    annlevy@sheba.health.gov.il   
Principal Investigator: Anat Achiron, MD, PhD         
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Anat Achiron, MD, PhD Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel
Principal Investigator: Yehuda Shoenfeld Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00230204     History of Changes
Other Study ID Numbers: SHEBA-05-3868-AA-CTIL
Study First Received: September 29, 2005
Last Updated: February 15, 2006
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Sheba Medical Center:
Multiple sclerosis
Antibodies
Serum
Infectious agents
Immunoglobulin G
Immunoglobulin M

Additional relevant MeSH terms:
Sclerosis
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Antibodies
Immunoglobulins
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 16, 2014